Background Historically, the prognosis for patients who have melanoma brain metastasis
(MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have …

Background Treatment options for patients with melanoma brain metastasis (MBM) have
changed significantly in the last decade. Few studies have evaluated changes in outcomes …

BACKGROUND The development of brain metastases is common for systemic treatment
failure in patients with melanoma and has been associated with a poor prognosis. Recent …

Background Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …

The remarkable advances in the systemic therapy of metastatic melanoma have now
extended the 1-year overall survival rate from 25% to nearing 85%. Systemic treatment in …

Background Up to 60% of melanoma patients develop melanoma brain metastases (MBM),
which traditionally have a poor diagnosis. Current treatment strategies include …

Melanoma brain metastases (MBM) are common and associated with a particularly poor
prognosis; they directly cause death in 60–70% of melanoma patients. In the past, systemic …

Patients with melanoma brain metastases (MBM) still have a very poor prognosis. Several
treatment modalities have been investigated in an attempt to improve the management of …

Opinion statement Brain metastases are a major clinical challenge occurring in up to 60% of
patients suffering from metastatic melanoma. They cause significant clinical symptoms and …

Melanoma is the third most common systemic cancer that leads to brain metastases. The
annual incidence of melanoma has increased over time, with brain metastases developing …